An antibody to human papillomavirus type 45 L1 protein and a preparation method thereof
By preparing monoclonal antibodies and double-antibody sandwich ELISA kits for HPV45 type L1 protein, the problem of insufficient protection of HPV45 type L1 protein was solved, and high specific recognition and quantitative detection of HPV45 type L1 protein was achieved, which improved HPV45 support for the research and development and production of type vaccines.
Patent Information
- Application Number
- CN202110811303.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-01-13
- Filing Date
- 2021-07-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-07-19
AI Technical Summary
The existing HPV vaccines have limited protective effects on HPV45 types and lack monoclonal antibodies specific and neutralizing activity against HPV45 type L1 protein, limiting the cross-protection effect on other high-risk types of HPV.
By preparing monoclonal antibodies against HPV45 type L1 protein and/or VLP, the specific identification and quantitative detection of HPV45 type L1 protein is achieved using hybridoma cell lines and a double antibody sandwich ELISA kit.
Monoclonal antibodies with high specificity and sensitivity were obtained, which can effectively recognize HPV45 VLP, and are used for clinical testing and vaccine quality inspection, enhancing the support for the research and development and production of HPV45 vaccines.
Smart Images

Figure CN114763378B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of molecular virology and immunology, and more specifically, to a human papillomavirus type 45 hybridoma cell line, a method for preparing a monoclonal antibody of human papillomavirus type 45 L1 protein and / or VLP, and a diagnostic kit prepared therefrom. Background Art
[0002] Human papillomavirus (HPV) is a group of small non-enveloped DNA viruses that infect human skin and mucosal epithelial tissues, and can induce warty hyperplasia and even benign or malignant tumors. There are many HPV subtypes, and more than 130 types have been isolated so far, and different types cause different clinical manifestations. According to the benign or malignant nature of the lesions induced after infection, they are divided into high-risk HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, etc.) and low-risk HPV (HPV6, 11, 40, 42, 43, 44, 54, etc.). Among the malignant lesions associated with high-risk HPV infection, cervical cancer in women has the highest incidence rate, which is second only to breast cancer worldwide, ranking second in gynecological malignancies and third in mortality.
[0003] High-risk types are integrated into the cell genome. Clinically, 95-99.7% of cervical cancer cases are related to high-risk HPV virus infection, that is, HPV infection is a prerequisite for the occurrence of cervical cancer. Scientific research has found that at least 20 high-risk HPVs are related to 95% of early invasive and invasive cervical cancers, especially HPV16 and HPV18, which are the main causes of cervical cancer. More than 70% of cervical cancers are related to these two subtypes. Low-risk types are not integrated into the cell genome, and mainly cause warty hyperplasia of the skin and mucous membranes, manifested as benign lesions such as condyloma acuminatum and flat warts. Epidemiological surveys and clinical studies have shown that the detection rates of HPV6 and HPV11 in genital condyloma acuminatum tissues are the highest, accounting for more than 70% of low-risk types.
[0004] At present, the most effective way to prevent HPV infection is to vaccinate with HPV vaccine, and the virus-like particle (VLP) vaccine based on the HPV major protein L1 currently on the market. VLP vaccine uses molecular biology technology to express one or more structural proteins of the virus. These structural proteins have natural autonomous assembly capabilities and can form spatial configurations and antigenic epitopes similar to natural virus particles, but without viral nucleic acid, strong immunogenicity, no infectivity, no risk of incomplete inactivation or virulence recovery, and a high density of viral antigens on the surface, which preserves conformational epitopes and can be presented to immune cells through the same pathway as the whole virus vaccine, effectively inducing the body's immune system to produce an immune protection response. Based on previous studies, it mainly induces gender-specific neutralizing antibodies, which can only prevent infection and related lesions of two high-risk viruses (HPV16, HPV18), and has no cross-protection effect or weak cross-protection effect on other types. The L1 protein and / or VLP of a HPV45 type provided by the present invention can induce specific neutralizing antibodies, and the antibodies produced have no cross-effect on the other eight high-risk viruses.
[0005] Currently available HPV vaccines include bivalent, quadrivalent and nine-valent vaccines. The nine-valent vaccine on the market contains HPV types 16, 18, 6, 11, 31, 33, 45, 52 and 58. HPV vaccines can stimulate the body to produce protective neutralizing antibodies, which are of great significance in effectively preventing HPV infection and cervical cancer.
[0006] In the process of HPV vaccine development, type identification, antigen content detection and in vitro efficacy determination are required. The methods can all adopt the double antibody sandwich ELISA. Therefore, in vaccine research, monoclonal antibodies are important tools for vaccine antigen quality control, especially antibodies with specificity and neutralizing activity, which play an irreplaceable and important role in vaccine development. The present invention provides a monoclonal antibody with specificity and neutralizing activity for HPV45. The ELISA detection kit prepared using two strains thereof can be specifically used to quickly identify HPV45 L1 protein, can be widely used in clinical testing and quality inspection in the current vaccine production process of vaccine manufacturers, and is of great significance to the health development of women and the development of HPV45 vaccines. Summary of the invention
[0007] The first aspect of the present invention provides a monoclonal antibody capable of recognizing the L1 protein and / or VLP of HPV45 and a hybridoma cell line producing the antibody.
[0008] The second aspect of the present invention provides a method for preparing a monoclonal antibody.
[0009] The third aspect of the present invention provides a method for preparing an antigen detection kit for HPV45 L1 protein and / or VLP.
[0010] A fourth aspect of the present invention provides a double antibody sandwich ELISA kit for detecting HPV45.
[0011] The present invention is achieved through the following technical solutions:
[0012] The monoclonal antibody provided by the present invention is directed against the HPV45 type L1 protein, which refers to the L1 protein encoding the papilloma HPV45 type. The nucleic acid base sequence of the HPV45 type L1 protein can be inserted into a prokaryotic expression vector by conventional molecular biological cloning methods. The expressed HPV45 type L1 protein can be polymerized to form a soluble polymer. The amino acid sequence of the HPV45 type L1 protein and the nucleic acid sequence encoding the L1 protein can be obtained through databases such as GenBank, Swiss-prot, EMBL.PIR Protein Data Base, PDBProtein Data Bank, or from the HPV sequence library (http: / / hpv-web.lanl.gov). Including but not limited to the production of HPV45 L1 protein using the Hansen yeast expression system described in the Chinese patent application with application publication number CN 104164447A, preparing virus-like particles (VLP) as immunogens, and preparing them. Specifically, HPV45 VLP is used as an immunogen to immunize mice, and hybridoma technology is used to obtain hybridoma cell lines that can continuously and stably secrete anti-HPV45 VLP through cell fusion and screening, and monoclonal antibodies are secreted by each cell line.
[0013] In the first aspect, in a preferred embodiment, the antibody 5F1-4G8 that recognizes the L1 protein and / or VLP of human papillomavirus type 45 is a monoclonal antibody produced by a hybridoma cell line obtained by fusion of immunized host spleen cells and myeloma cells, and the preservation number of the hybridoma cell is CGMCC NO.21987; classification name: hybridoma cell; preservation unit: General Microbiology Center of China National Culture Collection Administration; preservation unit address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing; preservation date: April 1, 2021.
[0014] The monoclonal antibody produced by the above hybridoma cell line comprises the amino acid sequence of the CDR of the heavy chain variable region having the CDRH1, CDRH2 or / and CDRH3 regions as shown in SEQ ID NO.1-3, and the amino acid sequence of the CDR of the light chain variable region having the CDRL1, CDRL2 or / and CDRL3 regions as shown in SEQ ID NO.4-6.
[0015] The monoclonal antibody produced by the above hybridoma cell line comprises an amino acid sequence of FR of the heavy chain variable region having FR1, FR2, FR3 and / or FR4 regions as shown in SEQ ID NOs.7-10, and an amino acid sequence of FR of the light chain variable region having FR1, FR2, FR3 and / or FR4 regions as shown in SEQ ID NOs.11-14.
[0016] The monoclonal antibody produced by the hybridoma cell line comprises the heavy chain variable region amino acid sequence shown in SEQ ID NO.15 and the light chain variable region amino acid sequence shown in SEQ ID NO.16.
[0017] The monoclonal antibody produced by the above hybridoma cell line comprises a nucleotide sequence of a CDR of a heavy chain variable region having CDRH1, CDRH2 or / and CDRH3 regions as shown in SEQ ID NOs.17-19, and a nucleotide sequence of a CDR of a light chain variable region having CDRL1, CDRL2 or / and CDRL3 regions as shown in SEQ ID NOs.20-22.
[0018] The monoclonal antibody produced by the above hybridoma cell line comprises a nucleotide sequence of FR of the heavy chain variable region having FR1, FR2, FR3 and / or FR4 regions as shown in SEQ ID NOs.23-26, and a nucleotide sequence of FR of the light chain variable region having FR1, FR2, FR3 and / or FR4 regions as shown in SEQ ID NOs.27-30.
[0019] The monoclonal antibody produced by the hybridoma cell line comprises a heavy chain variable region nucleotide sequence as shown in SEQ ID NO.31, and a light chain variable region nucleotide sequence as shown in SEQ ID NO.32.
[0020] In the second aspect, in another preferred embodiment, the second antibody 2A1-24C4 that recognizes the L1 protein and / or VLP of human papillomavirus type 45 is a monoclonal antibody produced by a hybridoma cell line obtained by fusion of another immunized host spleen cell and myeloma cell, and the preservation number of the hybridoma cell is CGMCC NO.21988; classification name: hybridoma cell; preservation unit: General Microbiology Center of China Culture Collection Administration; preservation unit address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing; preservation date: April 1, 2021.
[0021] The second antibody comprises an amino acid sequence of a CDR of a heavy chain variable region having CDRH1, CDRH2 or / and CDRH3 regions as shown in SEQ ID NOs.33-35, and an amino acid sequence of a CDR of a light chain variable region having CDRL1, CDRL2 or / and CDRL3 regions as shown in SEQ ID NOs.36-38.
[0022] The second antibody comprises an amino acid sequence of FR of a heavy chain variable region having FR1, FR2, FR3 or / and FR4 regions as shown in SEQ ID NOs.39-42, and an amino acid sequence of FR of a light chain variable region having FR1, FR2, FR3 or / and FR4 regions as shown in SEQ ID NOs.43-46.
[0023] The second antibody comprises a heavy chain variable region amino acid sequence as shown in SEQ ID NO.47 and a light chain variable region amino acid sequence as shown in SEQ ID NO.48.
[0024] The second antibody further comprises a nucleotide sequence of CDRs of the heavy chain variable region having CDRH1, CDRH2 or / and CDRH3 regions as shown in SEQ ID NOs.49-51, and a nucleotide sequence of CDRs of the light chain variable region having CDRL1, CDRL2 or / and CDRL3 regions as shown in SEQ ID NOs.52-54.
[0025] The second antibody comprises a nucleotide sequence of FR of a heavy chain variable region having FR1, FR2, FR3 or / and FR4 regions as shown in SEQ ID NOs.55-58, and a nucleotide sequence of FR of a light chain variable region having FR1, FR2, FR3 or / and FR4 regions as shown in SEQ ID NOs.59-62.
[0026] The second antibody comprises a heavy chain variable region nucleotide sequence as shown in SEQ ID NO.63 and a light chain variable region nucleotide sequence as shown in SEQ ID NO.64.
[0027] On the other hand, the present invention provides a kit for detecting L1 protein and / or VLP of HPV45, comprising two monoclonal antibodies in the two preferred embodiments disclosed in the present invention.
[0028] The kit for detecting L1 protein and / or VLP of HPV45 disclosed in the present invention is a double antibody sandwich ELISA kit for detecting L1 protein and / or VLP antigen of HPV45, and further comprises a detectable marker: a fluorescent substance, a colored substance and / or an enzyme.
[0029] Monoclonal antibodies to human papillomavirus type 45 L1 protein can be prepared as follows:
[0030] Step 1: Using the prepared human papillomavirus type 45 VLP protein as an immunogen, 6-8 week old female Balb / c mice were immunized after purification for a total of three times, with an interval of 14 days between each immunization, and collecting serum. The serum titer was detected by indirect ELISA method. According to the ELISA results, the tail vein of Balb / c female mice with high titer was selected, and immune spleen cells were prepared from the mice;
[0031] Step 2: Preparation of hybridoma cells. First, a myeloma cell (SP2 / 0) suspension is prepared and injected into female Balb / c mice. After the mice grow solid tumors, myeloma cells are prepared. The myeloma cells are fused with the immune spleen cells described in step 1 to prepare hybridoma cells. The hybridoma cell lines with high titers are detected and screened and cloned and expanded for culture;
[0032] Step 3: Collect the supernatant from the hybridoma cells cloned and expanded in step 2 and inject it into mice via the peritoneal cavity, collect the mouse ascites, purify it, and obtain the monoclonal antibody against human papillomavirus type 45 VLP through specific identification and neutralization activity detection.
[0033] Preparation method of human papillomavirus double antibody sandwich ELISA antigen detection kit:
[0034] The ELISA plate was coated with the monoclonal antibody 5F1-4G8 with specificity and no cross-talk as the capture antibody, the monoclonal antibody 2A1-24C4 with neutralizing activity was used as the detection antibody after being labeled with horseradish peroxidase, and the human papillomavirus type 45 VLP protein was used as the standard to prepare the standard curve control. The kit also includes concentrated washing solution, sample diluent, enzyme-labeled antibody diluent, substrate solution A, substrate solution B and stop solution.
[0035] The monoclonal antibody obtained in the present invention has good specificity. Experiments show that it has no cross-reaction with the other eight types of HPV. Therefore, the monoclonal antibody obtained in the present invention can be used for the specific detection of HPV45 VLP in the latest nine-valent vaccine on the market and vaccines or compositions including the HPV45 type.
[0036] The present invention adopts a double antibody sandwich method and utilizes two monoclonal antibodies to specifically detect and quantify HPV45 VLP. The present invention provides a kit for specific detection and quantification of HPV45 VLP, with a detection limit of 0.001953125 μg / mL and a linear range of 0.125-0.001953125 μg / mL. The kit has the advantages of high specificity and high sensitivity, and can accurately detect the level of bioactive HPV45 VLP in a sample. The kit will be widely used in clinical testing and quality inspection during vaccine production by vaccine manufacturers. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Attached Figure 1 : SDS-PAGE analysis results showed that the purity of each purified monoclonal antibody reached more than 90%.
[0038] Attached Figure 2 : Standard curve of paired identification experiment of various types of monoclonal antibodies, the ordinate is OD450 and the abscissa is the concentration of the standard.
[0039] Attached Figure 3 : Standard curve of specific identification experiment of antibodies 2A1-24C4 and 5F1-4G8, the ordinate is OD450, and the abscissa is the concentration of the standard.
[0040] Attached Figure 4 : ELISA double antibody sandwich method to detect HPV45 VLP standard curve, the ordinate is OD450, the abscissa is the standard concentration.
[0041] SEQ ID NO. 1-3 are the amino acid sequences CDRH1, CDRH2 and / or CDRH3 of the CDR of the heavy chain variable region of the antibody of the present invention;
[0042] SEQ ID NO. 4-6 are the amino acid sequences CDRL1, CDRL2 and / or CDRL3 of the CDR of the light chain variable region of the antibody of the present invention;
[0043] SEQ ID NO.7-10 are the amino acid sequences FR1, FR2, FR3 and / or FR4 of the heavy chain variable region of the antibody of the present invention;
[0044] SEQ ID NO.11-14 are the amino acid sequences FR1, FR2, FR3 and / or FR4 of the light chain variable region of the antibody of the present invention;
[0045] SEQ ID NO.15 is the amino acid sequence of the heavy chain variable region of the antibody of the present invention;
[0046] SEQ ID NO.16 is the amino acid sequence of the light chain variable region of the antibody of the present invention;
[0047] SEQ ID NO. 17-19 are the nucleotide sequences CDRH1, CDRH2 and / or CDRH3 of the CDR of the heavy chain variable region of the antibody of the present invention;
[0048] SEQ ID NO. 20-22 are the nucleotide sequences CDRL1, CDRL2 and / or CDRL3 of the CDR of the light chain variable region of the antibody of the present invention;
[0049] SEQ ID NO. 23-26 are the nucleotide sequences FR1, FR2, FR3 and / or FR4 of the heavy chain variable region of the antibody of the present invention;
[0050] SEQ ID NO. 27-30 are the nucleotide sequences FR1, FR2, FR3 and / or FR4 of the light chain variable region of the antibody of the present invention;
[0051] SEQ ID NO.31 is the nucleotide sequence of the heavy chain variable region of the antibody of the present invention;
[0052] SEQ ID NO.32 is the nucleotide sequence of the light chain variable region of the antibody of the present invention;
[0053] SEQ ID NO.33-35 are the amino acid sequences CDRH1, CDRH2 and / or CDRH3 of the CDR of the heavy chain variable region of the second antibody of the present invention;
[0054] SEQ ID NO.36-38 are the amino acid sequences CDRL1, CDRL2 and / or CDRL3 of the CDR of the light chain variable region of the second antibody of the present invention;
[0055] SEQ ID NO.39-42 are the amino acid sequences FR1, FR2, FR3 and / or FR4 of the heavy chain variable region of the second antibody of the present invention;
[0056] SEQ ID NO. 43-46 are the amino acid sequences FR1, FR2, FR3 and / or FR4 of the light chain variable region of the second antibody of the present invention;
[0057] SEQ ID NO.47 is the amino acid sequence of the heavy chain variable region of the second antibody of the present invention;
[0058] SEQ ID NO.48 is the amino acid sequence of the light chain variable region of the second antibody of the present invention;
[0059] SEQ ID NO. 49-51 are the nucleotide sequences CDRH1, CDRH2 and / or CDRH3 of the CDR of the heavy chain variable region of the second antibody of the present invention;
[0060] SEQ ID NO.52-54 are the nucleotide sequences CDRL1, CDRL2 and / or CDRL3 of the CDR of the light chain variable region of the second antibody of the present invention;
[0061] SEQ ID NO.55-58 are the nucleotide sequences FR1, FR2, FR3 and / or FR4 of the heavy chain variable region of the second antibody of the present invention;
[0062] SEQ ID NO.59-62 are the nucleotide sequences FR1, FR2, FR3 and / or FR4 of the light chain variable region of the second antibody of the present invention;
[0063] SEQ ID NO.63 is the nucleotide sequence of the heavy chain variable region of the second antibody of the present invention;
[0064] SEQ ID NO.64 is the nucleotide sequence of the light chain variable region of the second antibody of the present invention; Specific implementation methods
[0065] The following further describes the principles, features and contents of the present invention in conjunction with the examples, and the examples are only used to explain the present invention and should not be construed as limiting the present invention. If not otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the reagents without indicating the source are conventional reagents in the art or commercially available reagents, and the scientific and technical terms used in the text have the meanings generally understood by those skilled in the art. Those skilled in the art who are familiar with the present invention carry out non-essential improvements and adjustments to the embodiments according to the above-mentioned invention content, which still belong to the protection scope of the present invention. In order to better understand the present invention, the definition and explanation of the relevant terms are provided below.
[0066] The term "antibody" as used in the present invention refers to an immunoglobulin molecule generally composed of two pairs of polypeptide chains (each pair having a light (L) chain and a heavy (H) chain). Within the light chain and the heavy chain, the variable region and the constant region are connected by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (V H ) and the heavy chain constant region (C H ). The heavy chain constant region consists of three domains (C H 1. C H 2 and C H 3). Each light chain consists of a light chain variable region (V L ) and the light chain constant region (C L ). The light chain constant region consists of a domain C L Composition. H and V LThe V region can be further subdivided into regions of high variability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V L It consists of 3 CDRs and 4 FRs arranged from the amino terminus to the carboxyl terminus in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of each heavy chain / light chain pair form the antibody binding site. The term "antibody" is not limited to any particular method for producing antibodies.
[0067] The term "monoclonal antibody" used in the present invention refers to an antibody or an antibody fragment from a group of highly homologous antibody molecules. Monoclonal antibodies have high specificity for a single epitope on an antigen.
[0068] As used herein, "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably.
[0069] The term "HPVVLP" used in the present invention refers to virus-like particles assembled from HPV L1 proteins expressed in vitro, such as HPV45 L1-VLP refers to virus-like particles assembled from HPV45 type L1 proteins expressed in vitro.
[0070] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with specific embodiments.
[0071] Example 1. Establishment of hybridoma cell lines
[0072] 1. Animal immunization
[0073] 1) Antigen preparation: homemade antigen. HPV45 L1 protein was produced using the Hansen yeast expression system described in the Chinese patent application with application publication number CN104164447A. The purified HPV45 L1 protein sample was diluted 3 times with sterile water and a small drop was dropped on a wax plate. A copper mesh was taken so that the surface with the support membrane was in contact with the surface of the sample liquid, and it was allowed to stand for 1 minute before being taken out. The copper mesh was taken out, and excess droplets were removed with a filter paper strip and slightly dried. A 2% uranyl acetate solution was taken and a small drop was dropped on the wax plate. The copper mesh adsorbed with the sample was placed on the surface of the dye solution (the sample was in contact with the dye solution) and allowed to stand for 2 minutes. The copper mesh was taken out, and excess droplets were removed with a filter paper strip and dried under an incandescent lamp. Electron microscopy showed that it had self-assembled into virus-like particles (VLPs), and the virus-like particles were used as antigens.
[0074] Basic immunization: The antigen was mixed with Freund's complete adjuvant in equal volumes and fully emulsified, and then injected intraperitoneally into 6-8 week old Balb / c female mice at an immunization dose of 30 μg / mouse.
[0075] 2) Booster immunization: Booster immunization uses an emulsion of antigen and Freund's incomplete adjuvant. The first booster immunization is carried out 14 days after the basic immunization, the second booster immunization is carried out 14 days later, and the third booster immunization is carried out 13 days later. Each time, 30μg of the mixed emulsion of antigen and Freund's incomplete adjuvant is injected intraperitoneally.
[0076] 3) Tail vein: 0.1 mL / mouse, cell fusion was performed 3 days later.
[0077] 2. Preparation of hybridoma cells
[0078] The spleen cells of mice were collected by conventional methods and fused with SP2 / 0 cells at a ratio of 5:1 using PEG4000. They were cultured in HAT selection medium. After fusion for 5-7 days, the supernatant was taken and the hybridoma cell lines were screened by indirect ELISA. The positive clones were subcloned by limiting dilution method. The operation steps of indirect ELISA method are as follows:
[0079] 1) Coating: Add 0.5 μg / mL HPV45 VLP protein, 50 μL / well to the ELISA plate for coating and place in a 4°C refrigerator overnight;
[0080] 2) Blocking: Take out the coated plate, wash it twice with a plate washer, pat it dry, add blocking solution, 150 μL / well, and incubate it in a 37°C incubator for 2 h;
[0081] 3) Sample addition: Wash the ELISA plate sealed in the above step once with a plate washer, pat dry, add the sample to be tested, 100 μL / well, and set up positive control wells and negative control wells. Incubate in a 37°C incubator for 30 minutes;
[0082] 4) Secondary antibody: Wash the incubated ELISA plate three times with a plate washer and pat dry. Add goat anti-mouse IgG (H+L) secondary antibody at a dilution of 1:4000. Incubate in a 37°C incubator for 30 minutes;
[0083] 5) Color development: After the secondary antibody incubation in the above step, wash the ELISA plate 5 times, pat dry, mix the color development solution A and B in a 1:1 ratio, add 100 μL / well of the ELISA plate, and react for 10 minutes;
[0084] 6) Stop: Add 50 μL / well of stop solution, read the OD value at 450 nm using a microplate reader, and the clones with OD greater than 1.0 are considered positive clones.
[0085] 3. Establishment of hybridoma cell lines
[0086] The positive clones obtained in step 2 are further cloned, and the hybridoma cell lines are further cultured and subcultured in a culture medium containing 10% fetal bovine serum and 10×HT until the hybridoma cell lines can still grow well and be stably subcultured, thereby obtaining hybridoma cell lines that stably secrete monoclonal antibodies.
[0087] Example 2: Preparation and purification of monoclonal antibodies against HPV45
[0088] 1. Paraffin sensitization: Select Balb / c multiparous mice and sensitize them with paraffin 7 days before cell inoculation (paraffin oil can reduce the rejection reaction of mice to inoculated hybridoma cells and is conducive to the growth of hybridoma cells). Remove the needle from the 2mL syringe, draw 2.5mL of paraffin oil and fix the needle, with the bevel of the needle facing the direction of the syringe scale, and slowly inject 0.5mL into the peritoneum of each mouse.
[0089] 2. Cell inoculation: Take cells in good condition, discard the supernatant, add a certain amount of DMEM medium to disperse the adherent cells, centrifuge at 1000rpm for 5 minutes, discard the supernatant, resuspend with 2mL medium, take 10μL cells and add an equal volume of trypan blue reagent for counting. According to the counting results and the required total number of cells, take a certain volume of cell suspension into a centrifuge tube, centrifuge at 1000rpm for 5 minutes, discard the supernatant, add physiological saline to make the cell density 0.5×10 6 / mL, 0.5mL / mouse was injected intraperitoneally. The growth of ascites in mice was observed at any time. Generally, ascites was produced 7 days after cell inoculation.
[0090] 3. Ascites collection: The time for collecting ascites is determined according to the swelling of the mouse's abdomen and the state of the mouse, generally 7 days after inoculation. Grab the mouse vertically and pierce the mouse's abdomen with a No. 12 needle. The needle is inserted about 1 / 4 of the length. Then use tweezers to control the position of the needle so that the ascites flows through the needle into the centrifuge tube. Centrifuge at 8000rpm for 10 minutes, collect the ascites supernatant, and store it in a -20℃ refrigerator. Subsequently, ascites is collected every 1 day until the mouse dies or is in a poor state of being killed and there is basically no ascites. Generally, it is collected about 3 times.
[0091] 4. Purification of ascites: Purification was performed using the caprylic acid-ammonium sulfate method. The ascites was centrifuged (12000r / min for 30min), the supernatant was collected, and the precipitate was discarded. Accurately quantify the volume of ascites. A 50mM citric acid (pH 4.0) solution of 2 times the original ascites volume was added to the sample to adjust the pH after mixing to 4.6-4.8. Caprylic acid (60μL / mL ascites, calculated here according to the initial ascites volume) was added dropwise, stirring while adding to mix the solution evenly and precipitate completely. After standing at room temperature for 0.5 hours, the mixture was centrifuged (50mL centrifuge tube: 10000rpm centrifugation for 15min; 2mL centrifuge tube: 10000rpm centrifugation for 5min), the supernatant was carefully collected, the precipitate was discarded, the supernatant volume was recorded, and 2M Tris (pH 9.0) was added according to 0.03 times the supernatant volume to adjust the pH to neutral. Slowly add ammonium sulfate powder at 0.277g / mL, stirring while adding to fully dissolve the ammonium sulfate, and let it stand at room temperature for 0.5 hours until the precipitation is complete. Centrifuge the mixed solution (50mL centrifuge tube: 10000rpm centrifugation for 15min; 2mL centrifuge tube: 10000rpm centrifugation for 5min), discard the supernatant, and collect the precipitate. The precipitate was fully dissolved with PBS with 0.25 times the original volume of ascites, dialyzed with PBS, and the solution was changed 2 to 3 times. The dialysate was collected, centrifuged at 12000r / min for 15min, and the supernatant was taken to obtain the monoclonal antibody against HPV45 VLP. Samples were taken for SDS-PAGE and BCA method to measure the antibody concentration. The results showed that the purity of the purified monoclonal antibodies reached more than 90%, see the attached for details. Figure 1 .
[0092] Example 3: Specificity identification of various types of monoclonal antibodies (cross-test)
[0093] Add the prepared HPV45 VLP and other 8 types of HPV (HPV6, 11, 16, 18, 31, 33, 52, 58) VLP mixtures into 96-well ELISA plates, 0.5 μg / mL, 100 μL / well, and coat overnight at 4°C. Set up duplicate wells and negative control wells. Block at 37°C for 2 hours. Dilute each antibody sample 10 times with sample diluent. -3 ~10 -6, 100μL / well was added to the ELISA plate, covered with a sealing film and incubated in a 37℃ incubator for 45 minutes. Take the ELISA plate out of the incubator, discard the liquid in the well, add 300μL / well of washing solution, and wash the plate 5 times. After discarding the liquid in the well for the last time, pat it dry on toilet paper. Add 100μL / well of goat anti-mouse enzyme-labeled secondary antibody solution with a working concentration of 1:4000, cover with a cover film and incubate in a 37℃ incubator for 45 minutes. Take the ELISA plate out of the 37℃ incubator, discard the liquid in the well, add 300μL / well of washing solution, and wash the plate 10 times. After discarding the liquid in the well for the last time, pat it dry on toilet paper. Take the required volume of color substrate A solution and color substrate B solution in a 1:1 ratio, mix them evenly, add 100μL / well to the ELISA plate, and color at room temperature and avoid light for 10 minutes. Finally, take the required volume of stop solution and add it to the ELISA plate, 50μL / well. Place the ELISA plate in an ELISA instrument and measure the OD value at 450nm. Samples with an OD value greater than 0.5 are considered positive, and samples with an OD value less than or equal to 0.5 are considered negative. The cross-binding of each monoclonal antibody with HPV45 and other 8 types of HPV is observed, so that the monoclonal antibody that can specifically bind to HPV45 can be selected for the following further experiments.
[0094] The results of the cross-binding experiments of each monoclonal antibody with HPV45 and a mixture of other 8 HPV types are shown in Table 1. The results showed that the values of the prepared monoclonal antibodies 2A1-24C4, 2A1-13D5, 1E3-10D4, 5F1-4G8, 17E9-8G6, 2A1-28C6, 2A1-23G3, 2A1-32H3, 1E3-14B2, 1E3-1E7, 1E3-25G4, 26D1-5F10, 5F1-15C8, 5F1-9C5, 5F1-11E8, 17E9-33B6, 17E9-31B7, 17E9-29F8, 2B4-6G4, 2B4-6E2, 22F7-2G4 and 17H4-1F8 recognizing HPV45 VLP were all greater than 0.5, which were obviously positive results. The values for recognizing the other 8 types of HPV VLP were all less than 0.5, indicating a negative result; while the values for the other 8 types of monoclonal antibodies recognizing the mixture of other 8 types of HPV VLP were partially greater than 0.5, indicating that there was crossover with the other 8 types. Comprehensive consideration found that the monoclonal antibodies 2A1-24C4, 2A1-13D5, 1E3-10D4, 5F1-4G8 and 17E9-8G6 prepared by the present invention have good specificity for recognizing HPV45 VLP, no crossover with the other 8 types, and good binding to HPV45 within the dilution gradient range, and can be used for further research of the present invention.
[0095] Table 1 Specificity identification results of various types of monoclonal antibodies
[0096]
[0097]
[0098]
[0099] Example 4: Pairing and identification test of various types of monoclonal antibodies
[0100] HPV45 VLP was coated on a 96-well plate, and any antibody (such as 5F1-4G8) finally selected in Example 3 was used as the coating antibody, and the other types of enzyme-labeled antibodies (2A1-24C4-HRP, 2A1-13D5-HRP, 1E3-10D4-HRP, 5F1-4G8-HRP and 17E9-8G6-HRP) that can specifically bind to HPV45 were used as detection antibodies. ELISA experiments were performed, and the test was performed after screening and optimization using the checkerboard method identification test. The test results are shown in Table 2, and the standard curves of each group are shown in the attached Figure 2 As shown, the results show that after a series of screening, only 2A1-24C4 and 5F1-4G8 have no competition with the antigen binding epitope, indicating that 2A1-24C4 and 5F1-4G8 do not have the same antigen binding site and can form the antibody pair of the coating antibody and the detection antibody of the present invention.
[0101] Table 2 Pairing and identification results of various types of monoclonal antibodies
[0102]
[0103]
[0104]
[0105] Example 5: ELISA method to detect the reactivity of antibodies and HPV45 VLPs
[0106] The indirect ELISA method is used to verify whether the reactivity of the purified monoclonal antibody with HPV45 VLP is good and whether it can be detected quickly and conveniently. At the same time, the reactivity of the monoclonal purified antibody with HPV45 VLP at different concentrations can also preliminarily reflect the affinity of the antibody.
[0107] HPV45 VLP was coated on a 96-well plate at 100 μL / well, and then antibodies with final concentrations of 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL and 0.0625 μg / mL were added to each well, with 3 parallels for each concentration, and a negative control was set up at the same time. The binding strength of each monoclonal purified antibody to HPV45 VLP was detected by ELISA. The results showed that the 25 antibodies could bind to HPV45 VLP within the concentration range used in this experiment, and the signal intensity was greater than 1. It can be preliminarily seen that among the 25 antibodies, antibody 2A1-24C4 and antibody 5F1-4G8 had higher binding strength to HPV45 VLP, as shown in Table 3.
[0108] Table 3 ELISA detection of antibody binding strength to HPV45 VLP
[0109]
[0110]
[0111] *All values are averages of duplicate wells
[0112] Example 6: Neutralizing activity detection of antibodies
[0113] The neutralizing activity of each antibody strain was detected by the pseudovirus-cell neutralization model. First, each subtype antibody was diluted 100, 400, 1600, and 6400 times with complete culture medium, and blank wells, negative control wells, and positive control wells were set up. Then, equal volumes of supernatant and pseudovirus were added to the 96-well plate, mixed on a microplate oscillator, incubated at 4°C for 1 hour, and then transferred to a 37°C cell culture incubator for 10 minutes. Take 100 μL of the mixture and add it to the 96-well plate pre-plated with 293FT cells, and culture it in a cell culture incubator for 72 hours. Then, the entire 96-well plate was scanned and counted using an enzyme-linked immunospot analyzer. The pseudovirus contains a GFP reporter gene, which is green under a fluorescence microscope. If the antibody has neutralizing activity, it can prevent pseudovirus infection and make the cells non-color.
[0114] The results are shown in Table 4. The results show that except for 17H4-1F8 with inhibition rates of 98% and 86% when diluted 1600 times and 6400 times, the inhibition rates of other clones at each dilution gradient were 100%. These results indicate that these monoclonal antibodies all have neutralizing activity.
[0115] Table 4 Inhibition rate of each subtype antibody
[0116]
[0117]
[0118] Example 7. Specificity Identification of Antibodies 2A1-24C4 and 5F1-4G8
[0119] Add the prepared standard and test samples (HPV45 and other 8 types of HPV (HPV6, 11, 16, 18, 31, 33, 52, 58) VLP) to the coated plate at 100 μL / well, and set up duplicate wells and negative control wells. Cover with a sealing film and incubate in a 37°C incubator for 45 minutes. Take the ELISA plate out of the incubator, discard the liquid in the well, add 300 μL / well of washing solution, and wash the plate 5 times. After discarding the liquid in the well for the last time, pat it dry on toilet paper. Add 100 μL / well of the prepared enzyme-labeled antibody solution (5F1-4G8 and 2A1-24C4), cover with a cover film, and incubate in a 37°C incubator for 45 minutes. Take the ELISA plate out of the 37°C incubator, discard the liquid in the well, add 300 μL / well of washing solution, and wash the plate 10 times. After discarding the liquid in the well for the last time, pat it dry on toilet paper. Take the required volume of color substrate A solution and color substrate B solution in a 1:1 ratio, mix them, add 100μL / well to the ELISA plate, and color at room temperature in the dark for 5 minutes. Finally, take the required volume of stop solution and add it to the ELISA plate, 50μL / well. Put the ELISA plate into the ELISA reader and measure the OD value at 450nm. The sample test result with an OD value greater than 0.5 is judged as positive. This is used to evaluate whether antibodies 5F1-4G8 and 2A1-24C4 have the specificity to bind to HPV45.
[0120] The specificity test results of the antibodies are shown in Table 5, and the standard curve is shown in the attached Figure 3 As shown. The results show that the values of the prepared monoclonal antibodies 5F1-4G8 and 2A1-24C4 in recognizing HPV45 VLP are all greater than 0.5, which is a clear positive result. The values of recognizing the other 8 types of HPV VLP are all less than 0.5, indicating a negative result. This shows that the monoclonal antibodies 5F1-4G8 and 2A1-24C4 prepared by the present invention have good specificity for recognizing HPV45 VLP, and 5F1-4G8 is slightly better than 2A1-24C4.
[0121] Table 5 Specificity of Antibodies by ELISA (OD450)*
[0122]
[0123] *All values are averages of duplicate wells
[0124] Example 8. Affinity Identification of Antibodies 5F1-4G8 and 2A1-24C4
[0125] The affinity of antibodies 5F1-4G8 and 2A1-24C4 was identified by analyzing the kinetics of antigen-antibody binding and dissociation. The binding rate constant Kon, dissociation rate constant Koff and dissociation constant Kd of monoclonal antibodies 5F1-4G8 and 2A1-24C4 with HPV45 VLP were calculated using the GE BIAcore 3000 biomacromolecule interaction analyzer to reflect the strength of the binding between the antibody and HPV45 VLP.
[0126] HPV45 VLP was diluted to 40 μg / mL with 10 mM sodium acetate buffer at pH 4.5, and coupled to the chip surface according to the manufacturer's instructions. Antibodies were diluted to an appropriate concentration with PBS buffer. During the test, the antibody was injected for 60 seconds, then bound for 60 seconds, dissociated for 500 seconds, and finally the chip was regenerated with 10 mM sodium acetate buffer at pH 5.0. The data were analyzed for the kinetics of antigen-antibody binding using BIAcore 3000 Evaluation software according to the instructions. The affinity test results of antibodies 5F1-4G8 and 2A1-24C4 with HPV45 VLP are shown in Table 6. The results show that 5F1-4G8 and 2A1-24C4 antibodies are specific antibodies that only bind to HPV45 VLP and do not bind to the other 8 HPV VLPs.
[0127] Table 6 Affinity identification of antibodies 5F1-4G8 and 2A1-24C4
[0128]
[0129] Example 9. Subtype Identification of Clone 5F1-4G8 and Clone 2A1-24C4
[0130] The IgG subtypes of monoclonal antibodies 5F1-4G8 and 2A1-24C4 were identified by indirect ELISA using antibodies against various mouse IgG subtypes. The results showed that 5F1-4G8 cloned as IgG3 and 2A1-24C4 as IgG1. The results are shown in Table 7. (OD450 greater than 1 is the confirmed subtype)
[0131] Table 7 ELISA identification of antibody subtypes (OD450 value*)
[0132]
[0133] *All values are averages of duplicate wells
[0134] Example 10: Determination of variable region sequences of clones 2A1-24C4 and 5F1-4G8
[0135] Before sequencing the variable regions of cells, the cell supernatants of the two cell lines were first tested for subtypes. After confirming that they were of a single subtype, cryopreserved cells in the logarithmic growth phase were taken, revived by centrifugation and collected. Each 5×10 6 After adding 1 mL of Total RNA Extractor (Trizol) to each cell, the variable region sequencing was commissioned to Nanjing GenScript Sequencing Unit.
[0136] See the sequence listing for the sequence.
[0137] Using the above-identified sequences, various genetically engineered antibodies, such as chimeric antibodies, humanized antibodies, single-chain antibodies, diabodies, etc., can be prepared through known antibody engineering techniques, while retaining the biological properties of the monoclonal antibodies from which they are derived.
[0138] Example 11: Assembly of HPV45 Detection Kit
[0139] 1. Coating: dilute the antibody to 0.5 μg / mL with 1XPBS coating solution, add 100 μL / well to the ELISA plate, and place in a 4°C refrigerator for 18-24 hours;
[0140] 2. Wash the plate: Take out the ELISA plate from the refrigerator and wash it twice with a plate washer, 1X washing solution, 250 μL / well;
[0141] 3. Blocking: Wash twice with 1X washing solution and pat dry, then block overnight at 4℃ for 18-24 hours with 150μL / well;
[0142] 4. Drying: After sealing for 18-24 hours, shake off the liquid in the plate, pat it dry and place it in a drying room (make sure the humidity in the drying room is below 30%, the temperature is 30℃±37℃, and record the temperature and humidity at any time during the period) until the plate is completely dry, at least 4.5 hours;
[0143] 5. Sealing the plate: Put the dried ELISA plate in an aluminum foil bag with a label (the label must have the name, ELISA plate production batch number, and expiration date), and prepare a bag of desiccant, seal the plate with a sealing machine, and store the sealed plate in a refrigerator at 4°C. The validity period is 1 year;
[0144] 6. Label 2A1-24C4 with horseradish peroxidase to obtain 2A1-24C4-HRP and store it at -20°C.
[0145] The monoclonal antibody 5F1-4G8 with specificity and no cross-talk was used as the coating antibody, the monoclonal antibody 2A1-24C4 with neutralizing activity was used as the detection antibody after being labeled with horseradish peroxidase, and the recombinant human papillomavirus-45 VLP protein was used as the standard to prepare the standard curve control.
[0146] Example 12: Linearity and Repeatability Test of HPV45 Detection Kit
[0147] The ELISA double antibody sandwich method was used, with 5F1-4G8 as the coating antibody and 2A1-24C4-HRP as the detection antibody. The ELISA detection method was determined. The detection linear range of the kit is shown in Table 8, and the standard curve is shown in the attached figure. Figure 4 As shown, the linear range of the kit of the present invention is 0.125-0.001953125 μg / mL.
[0148] Table 8 Kit linear range detection
[0149]
[0150]
[0151] The antigen was diluted in turn according to 0.125 μg / mL, 0.0625 μg / mL, 0.03125 μg / mL, 0.0156 μg / mL, 0.0078 μg / mL, 0.0039 μg / mL and 0.0019 μg / mL, and the inter-batch and intra-batch repeatability experiments were performed according to the above ELISA experimental operation steps. The intra-batch and inter-batch experiments of each sample were tested and the standard deviation and coefficient of variation were calculated. The results are shown in Table 9, and the average standard deviation is 5.125, and the average coefficient of variation is 10%, which is less than 15%. It is shown that the double antibody sandwich ELISA antigen detection method established by the present invention has good repeatability.
[0152] Table 9 Kit repeatability test
[0153]
[0154]
[0155] Example 13, HPV45 Detection Kit Assay Procedure
[0156] 1. Prepare samples
[0157] 1) Preparation of washing solution: Take out 50 mL of 20-fold concentrated washing solution, add distilled water, dilute to 1 L and mix thoroughly for later use;
[0158] 2) Sample diluent;
[0159] 3) Enzyme-labeled antibody diluent;
[0160] 4) Dilute the standard with sample diluent, set the dilution gradient, and set aside;
[0161] 5) Dilute the enzyme-labeled antibody with enzyme-labeled antibody diluent, take an appropriate amount of enzyme-labeled antibody and dilute it 15,000 times for later use.
[0162] 2. Determination steps
[0163] 1) Sample addition: Add the prepared standard and sample to be tested into the coated plate at 100 μL / well, cover with sealing film and place in a 37°C incubator for 45 minutes;
[0164] 2) Add enzyme-labeled antibody: Take the ELISA plate out of the incubator, discard the liquid in the well, add 300μL / well of washing solution, wash the plate 5 times, soak for 30 seconds each time. After discarding the liquid in the well for the last time, pat dry on absorbent paper. Add 100μL / well of the prepared enzyme-labeled antibody solution, cover the plate with a cover film and incubate in a 37℃ incubator for 45 minutes;
[0165] 3) Color development: Take the ELISA plate out of the 37°C incubator, discard the liquid in the wells, add 300μL / well of washing solution, wash the plate 5 times, soak for 30 seconds each time. After discarding the liquid in the wells for the last time, pat dry on absorbent paper. Take the required volume of color substrate A solution and color substrate B solution in a 1:1 ratio, mix them, add 100μL / well to the ELISA plate, and incubate in a 37°C incubator away from light for 10 minutes;
[0166] 4) Stop the reaction: add the required volume of stop solution to the ELISA plate, 50 μL / well;
[0167] 5) Determination: Place the ELISA plate into an ELISA reader, set 630 nm as the reference wavelength, measure the absorbance at a wavelength of 450 nm, and record the measurement results;
[0168] 6) Result determination:
[0169] ① Four-parameter fitting curve R of standard product 2 ≥0.9801;
[0170] ②The linear range of the method is 0.125-0.001953125μg / mL, the detection limit is 0.001953125μg / mL, the test results above 0.001953125μg / mL are judged as positive, and the OD value of the negative control is ≤0.100;
[0171] ③ The test results of different concentration ranges of the test sample must all be within the linear range of the standard curve. Points above or below the linear range have no reference significance. The final quantitative result of the test sample is the average value of the points within multiple concentration ranges.
[0172] ④ The above three points must be met at the same time, unless otherwise specified. Sequence Listing <110> Jiangsu Ruike Biotechnology Co., Ltd.; Beijing Anbaisheng Biotechnology Co., Ltd. <120> An antibody to human papillomavirus type 45 L1 protein and a preparation method thereof <130> 2020 <150> 2021100426377 <151> 2021-01-13 <160> 64 <170> SIPOSequenceListing 1.0 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <400> 1 Asp Tyr Ser Met His 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <400> 2 Val Ile Ser Thr Tyr Tyr Gly Asp Ala Arg Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 3 <211> 12 <212> PRT <213> Artificial sequence <400> 3 Ser Tyr Asp Gly Lys Gly Ile Tyr Gly Met Asp Tyr 1 5 10 <210> 4 <211> 11 <212> PRT <213> Artificial sequence <400> 4 Arg Ala Ser Gln Asp Ile Arg Asn Asn Leu Asn 1 5 10 <210> 5 <211> 7 <212> PRT <213> Artificial sequence <400> 5 Tyr Thr Ser Thr Leu His Ser 1 5 <210> 6 <211> 9 <212> PRT <213> Artificial sequence <400> 6 Gln Gln Gly Asn Thr Leu Pro Arg Thr 1 5 <210> 7 <211> 30 <212> PRT <213> Artificial sequence <400> 7 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Val 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr 20 25 30 <210> 8 <211> 14 <212> PRT <213> Artificial sequence <400> 8 Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly 1 5 10 <210> 9 <211> 32 <212> PRT <213> Artificial sequence <400> 9 Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser Ser Thr Ala Tyr Met Glu 1 5 10 15 Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys Val Arg 20 25 30 <210> 10 <211> 11 <212> PRT <213> Artificial sequence <400> 10 Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 1 5 10 <210> 11 <211> twenty three <212> PRT <213> Artificial sequence <400> 11 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys 20 <210> 12 <211> 15 <212> PRT <213> Artificial sequence <400> 12 Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr 1 5 10 15 <210> 13 <211> 32 <212> PRT <213> Artificial sequence <400> 13 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser 1 5 10 15 Leu Thr Ile Ser Asn Leu Asp Gln Glu Asp Ile Ala Thr Tyr Phe Cys 20 25 30 <210> 14 <211> 10 <212> PRT <213> Artificial sequence <400> 14 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 1 5 10 <210> 15 <211> 140 <212> PRT <213> Artificial sequence <400> 15 Met Gly Trp Ser Trp Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg 20 25 30 Pro Gly Val Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe 35 40 45 Thr Asp Tyr Ser Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu 50 55 60 Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asp Ala Arg Tyr Asn 65 70 75 80 Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile 100 105 110 Tyr Tyr Cys Val Arg Ser Tyr Asp Gly Lys Gly Ile Tyr Gly Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 130 135 140 <210> 16 <211> 126 <212> PRT <213> Artificial Sequence <400> 16 Met Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Leu Cys Phe Gln Gly 1 5 10 15 Ala Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala 20 25 30 Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile 35 40 45 Arg Asn Asn Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys 50 55 60 Leu Leu Ile Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn 85 90 95 Leu Asp Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr 100 105 110 Leu Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 115 120 125 <210> 17 <211> 15 <212> DNA <213> Artificial sequence <400> 17 gattattcta tgcac 15 <210> 18 <211> 51 <212> DNA <213> Artificial sequence <400> 18 gttattagta cttactatgg tgatgctagg tacaaccaga agttcaaggg c 51 <210> 19 <211> 36 <212> DNA <213> Artificial sequence <400> 19 tcttatgatg gtaaagggat ctatggtatg gactac 36 <210> 20 <211> 33 <212> DNA <213> Artificial sequence <400> 20 aggcaagtc aggacattag gaataattta aac 33 <210> twenty one <211> twenty one <212> DNA <213> Artificial sequence <400> twenty one tacacatcaa cactacactc a 21 <210> twenty two <211> 27 <212> DNA <213> The snowstorm <400> 22 caacagggta atacgcttcc tcggacg <210> 23 <211> 90 <212> DNA <213> The snowstorm <400> 23 caggtccagc tgcagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact <210> 24 <211> 42 <212> DNA <213> A snowstorm <400> 24 tgggtgaaac agagtcatgg aaagagtcta gagtggattg of <210> 25 <211> 96 <212> DNA <213> The snowstorm <400> 25 60. aaggccacaa tgactgtaga caaatcctcc agcacagcct atatggaact tgccagactg acatctgagg attctgccat ctattactgt gtaaga <210> 26 <211> 33 <212> DNA <213> The snowstorm <400> 26 tggggtcaag gaacctcagt caccgtctcc tca <210> 27 <211> 69 <212> DNA <213> Artificial sequence <400> 27 gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 atcagttgc 69 <210> 28 <211> 45 <212> DNA <213> Artificial sequence <400> 28 tggtatcagc agaaaccaga tggaactgtt aaactcctga tctac 45 <210> 29 <211> 96 <212> DNA <213> Artificial sequence <400> 29 ggagtcccat caaggttcag tggcagtggg tctggaacag attattctct caccattagc 60 aacctggacc aagaagatat tgccacttac ttttgc 96 <210> 30 <211> 30 <212> DNA <213> Artificial sequence <400> 30 ttcggtggag gcaccaagct ggaaatcaaa 30 <210> 31 <211> 420 <212> DNA <213> Artificial sequence <400> 31 atgggttgga gctggatcat cttctttctg gtagcaacag ctacaggtgt gcactcccag 60 gtccagctgc agcagtctgg ggctgagctg gtgaggcctg gggtctcagt gaagatttcc 120 tgcaagggtt ctggctacac attcactgat tattctatgc actgggtgaa acagagtcat 180 ggaaagagtc tagagtggat tggagttatt agtacttact atggtgatgc taggtacaac 240 cagaagttca agggcaaggc cacaatgact gtagacaaat cctccagcac agcctatatg 300 gaacttgcca gactgacatc tgaggattct gccatctatt actgtgtaag atcttatgat 360 ggtaaaggga tctatggtat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 420 <210> 32 <211> 378 <212> DNA <213> Artificial Sequence <400> 32 atgtcctctg ctcagttcct tggtctcctg ttgctctgtt ttcaaggtgc cagatgtgat 60 atccagatga cacagactac atcctccctg tctgcctctc tgggagacag agtcaccatc 120 agttgcaggg caagtcagga cattaggaat aatttaaact ggtatcagca gaaaccagat 180 ggaactgtta aactcctgat ctactacaca tcaacactac actcaggagt cccatcaagg 240 ttcagtggca gtgggtctgg aacagattat tctctcacca ttagcaacct ggaccaagaa 300 gatattgcca cttacttttg ccaacagggt aatacgcttc ctcggacgtt cggtggaggc 360 accaagctgg aaatcaaa 378 <210> 33 <211> 5 <212> PRT <213> Artificial sequence <400> 33 Ser Tyr Trp Met His 1 5 <210> 34 <211> 17 <212> PRT <213> Artificial sequence <400> 34 Glu Ile Asn Pro Gly Tyr Gly Leu Ser Asn Tyr Asn Glu Asn Phe Lys 1 5 10 15 Thr <210> 35 <211> 13 <212> PRT <213> Artificial sequence <400> 35 His Tyr Gly Thr Ser Asn Asp Tyr Tyr Ala Leu Asp Tyr 1 5 10 <210> 36 <211> 15 <212> PRT <213> Artificial sequence <400> 36 Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His 1 5 10 15 <210> 37 <211> 7 <212> PRT <213> Artificial sequence <400> 37 Tyr Ala Ser Asn Leu Gln Ser 1 5 <210> 38 <211> 9 <212> PRT <213> Artificial sequence <400> 38 Gln His Ser Trp Glu Ile Pro Trp Thr 1 5 <210> 39 <211> 30 <212> PRT <213> Artificial sequence <400> 39 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr 20 25 30 <210> 40 <211> 14 <212> PRT <213> Artificial sequence <400> 40 Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly 1 5 10 <210> 41 <211> 32 <212> PRT <213> Artificial sequence <400> 41 Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Val Tyr Met Gln 1 5 10 15 Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg 20 25 30 <210> 42 <211> 11 <212> PRT <213> Artificial sequence <400> 42 Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 1 5 10 <210> 43 <211> twenty three <212> PRT <213> Artificial sequence <400> 43 Asp Ile Val Leu Thr Gln Ser Pro Thr Ser Leu Val Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys 20 <210> 44 <211> 15 <212> PRT <213> Artificial sequence <400> 44 Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys 1 5 10 15 <210> 45 <211> 32 <212> PRT <213> Artificial sequence <400> 45 Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 1 5 10 15 Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys 20 25 30 <210> 46 <211> 10 <212> PRT <213> Artificial sequence <400> 46 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 1 5 10 <210> 47 <211> 141 <212> PRT <213> Artificial sequence <400> 47 Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Ala Asp 1 5 10 15 Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys 20 25 30 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Glu Ile Asn Pro Gly Tyr Gly Leu Ser Asn Tyr Asn 65 70 75 80 Glu Asn Phe Lys Thr Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr 85 90 95 Thr Val Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Ala Arg His Tyr Gly Thr Ser Asn Asp Tyr Tyr Ala Leu 115 120 125 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 130 135 140 <210> 48 <211> 131 <212> PRT <213> Artificial Sequence <400> 48 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Thr Ser Leu Val 20 25 30 Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser 35 40 45 Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro 50 55 60 Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Gln Ser 65 70 75 80 Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95 Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys 100 105 110 Gln His Ser Trp Glu Ile Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125 Glu Ile Lys 130 <210> 49 <211> 15 <212> DNA <213> Artificial sequence <400> 49 agctactgga tgcac 15 <210> 50 <211> 51 <212> DNA <213> Artificial sequence <400> 50 gagattaatc ctggctacgg tcttagtaac tacaatgaga acttcaagac c 51 <210> 51 <211> 39 <212> DNA <213> Artificial sequence <400> 51 cactacggta ctagtaacga ttactatgct ttggactac 39 <210> 52 <211> 45 <212> DNA <213> Artificial sequence <400> 52 agggccagcc aaagtgtcag tacatctagt tatagttata tgcac 45 <210> 53 <211> twenty one <212> DNA <213> Artificial sequence <400> 53 tatgcatcca acctacaatc t 21 <210> 54 <211> 27 <212> DNA <213> Artificial sequence <400> 54 cagcacagtt gggagattcc gtggacg 27 <210> 55 <211> 90 <212> DNA <213> Artificial sequence <400> 55 caggtccaac tgcagcagcc tggggctgaa ctggtgaagc ctggggcttc agtgaagctg 60 tcctgcaagg cttccggcta cagtttcacc 90 <210> 56 <211> 42 <212> DNA <213> Artificial sequence <400> 56 tgggtgaagc agaggcctgg acaaggcctt gagtggattg ga 42 <210> 57 <211> 96 <212> DNA <213> Artificial sequence <400> 57 aaggccacac tgactgtaga taaatcctcc accacagtct acatgcaact cagcagcctg 60 acatctgagg actctgcggt ctattactgt gcaaga 96 <210> 58 <211> 33 <212> DNA <213> Artificial sequence <400> 58 tggggtcaag gaacctcagt caccgtctcc tca 33 <210> 59 <211> 69 <212> DNA <213> Artificial sequence <400> 59 60. gacattgtgc tgacacagtc tcctacttcc ttagttgtat ctctggggca gagggccacc atctcatgc 69 <210> 60 <211> 45 <212> DNA <213> The snowstorm <400> 60 tggtaccaac agaaaccagg acagccaccc aaactcctca tcaag <210> 61 <211> 96 <212> DNA <213> The snowstorm <400> 61 ggggtccctg tcaggttcag tggcagtggg tctgggacag acttcaccct caacatccat cctgtggagg aggaggatac tgcaacatat tactgt <210> 62 <211> 30 <212> DNA <213> The snowstorm <400> 62 ttcggtggag gcaccaagct ggaaatcaaa <210> 63 <211> 423 <212> DNA <213> The snowstorm <400> 63 atgggatgga gctatatcat cctctttttg gtagcaacag ctgcagatgt ccactcccag gtccaactgc agcagcctgg ggctgaactg gtgaagcctg gggcttcagt gaagctgtcc tgcaaggctt ccggctacag tttcaccagc tactggatgc actgggtgaa gcagaggcct 180 ggacaaggcc ttgagtggat tggagagatt aatcctggct acggtcttag taactacaat 240 gagaacttca agaccaaggc cacactgact gtagataaat cctccaccac agtctacatg 300 caactcagca gcctgacatc tgaggactct gcggtctatt actgtgcaag acactacggt 360 actagtaacg attactatgc tttggactac tggggtcaag gaacctcagt caccgtctcc 420 tca 423 <210> 64 <211> 393 <212> DNA <213> Artificial Sequence <400> 64 atggagacag acacactcct gctatgggtg ctgctgctct gggttccagg ttccactggt 60 gacattgtgc tgacacagtc tcctacttcc ttagttgtat ctctggggca gagggccacc 120 atctcatgca gggccagcca aagtgtcagt acatctagtt atagttatat gcactggtac 180 caacagaaac caggacagcc acccaaactc ctcatcaagt atgcatccaa cctacaatct 240 ggggtccctg tcaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 300 cctgtggagg aggaggatac tgcaacatat tactgtcagc acagttggga gattccgtgg acgttcggtg gaggcacca gctggaatc aaa
Claims
1. An antibody that binds to L1 protein and / or VLP of human papillomavirus HPV45, characterized in that: The amino acid sequences of CDRH1, CDRH2 and CDRH3 in the CDR of the antibody heavy chain variable region are shown in SEQ ID NOs.1-3, and the amino acid sequences of CDRL1, CDRL2 and CDRL3 in the CDR of the antibody light chain variable region are shown in SEQ ID NOs.4-6.
2. The antibody binding to L1 protein and / or VLP of human papillomavirus HPV45 according to claim 1, characterized in that: The amino acid sequences of FR1, FR2, FR3 and FR4 in the FR region of the antibody heavy chain variable region are shown in SEQ ID NOs.7-10, and the amino acid sequences of FR1, FR2, FR3 and FR4 in the FR region of the antibody light chain variable region are shown in SEQ ID NOs.11-14.
3. The antibody according to claim 2, characterized in that The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
16.
4. The antibody according to claim 3, characterized in that The antibody is a monoclonal antibody produced by a hybridoma cell line obtained by fusion of immunized host spleen cells and myeloma cells. The deposit number of the hybridoma cell is CGMCCNO.21987.
5. A kit for detecting L1 protein and / or VLP of HPV45, characterized in that: The kit comprises the antibody according to any one of claims 1 to 4.
6. The kit according to claim 5, characterized in that The kit further comprises a second antibody that binds to the L1 protein and / or VLP of HPV45.
7. The kit according to claim 6, characterized in that The amino acid sequences of CDRH1, CDRH2 and CDRH3 in the CDR of the heavy chain variable region of the second antibody are shown in SEQ ID NOs.33-35, and the amino acid sequences of CDRL1, CDRL2 and CDRL3 in the CDR of the light chain variable region of the second antibody are shown in SEQ ID NOs.36-38.
8. The kit according to claim 7, characterized in that The amino acid sequences of FR1, FR2, FR3 and FR4 in the FR of the heavy chain variable region of the second antibody are shown in SEQ ID NOs.39-42, and the amino acid sequences of FR1, FR2, FR3 and FR4 in the FR of the light chain variable region of the second antibody are shown in SEQ ID NOs.43-46.
9. The kit according to claim 8, characterized in that The amino acid sequence of the heavy chain variable region of the second antibody is shown in SEQ ID NO.47, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
48.
10. The kit according to claim 9, characterized in that The second antibody is a monoclonal antibody produced by a hybridoma cell line obtained by fusion of immunized host spleen cells and myeloma cells. The deposit number of the hybridoma cell is CGMCC NO.21988.
11. The kit according to any one of claims 5 to 10, further comprising a detectable label: a radioisotope, a luminescent substance, a colored substance and / or an enzyme.
12. The kit according to any one of claims 5 to 10, characterized in that The kit is an ELISA kit, comprising a capture antibody and a detection antibody, wherein the capture antibody is the antibody according to any one of claims 1 to 4, and the detection antibody is the second antibody according to any one of claims 6 to 10.
13. Use of the antibody according to any one of claims 1 to 4, or the kit according to any one of claims 5 to 10, in the preparation of a detection reagent for HPV45 L1 protein and / or VLP.
